Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the US and worldwide. Against this backdrop, many look to the expanding market for biosimilars-follow-on products to biologic drugs-as a vehicle for controlling pharmaceutical spending. This study...
Author(s) : Stern, A. D.; Chen, J. L.; Ouellet, M.; Trusheim, M. R.; El-Kilani, Z.; Jessup, A.; Berndt, E. R.
Publisher : People-to-People Health Foundation, Project Hope, Bethesda, USA
Journal article : Health Affairs 2021 Vol.40 No.6 pp.989-999 ref.26